An AllTrials project

NCT04530136: An ongoing trial by Pharming Technologies B.V.

This trial is ongoing. It must report results 2 months, 2 weeks from now.

Full data

Full entry on ClinicalTrials.gov NCT04530136
Title Recombinant Human C1 Esterase Inhibitor (Ruconest®) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial in the United States (PROTECT-COVID-19-US)
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date Nov. 30, 2020
Completion date Aug. 15, 2021
Required reporting date Aug. 15, 2022, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov May 11, 2022
Days late None